SCHEMBL31269372

SCHEMBL31269372

CC(CCc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2cccc(Cl)c2)c(Cl)c1)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.35
▸ PDE10A Q9Y233 1/20 0.34
▸ PIK3CD O00329 2/20 0.34
▸ PDE1B Q01064 2/20 0.33
▸ PTGDR2 Q9Y5Y4 1/20 0.33
▸ HTR6 P50406 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR7 P34969 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ PPARG P37231 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ NCOA1 Q15788 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ NCOA3 Q9Y6Q9 1/20 0.32
▸ FFAR1 O14842 1/20 0.32
▸ FFAR4 Q5NUL3 1/20 0.32
▸ CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31268939 0.96 CNR1 (0.35) CNR1PDE10APIK3CDPDE1BPTGDR2
SCHEMBL30983374 0.90 CNR1 (0.35) CNR1PIK3CDPTGDR2HTR6HTR1A
SCHEMBL30983474 0.90 CNR1 (0.35) CNR1PIK3CDPTGDR2HTR6HTR1A
SCHEMBL30983500 0.90 CNR1 (0.35) CNR1PIK3CDPTGDR2HTR6HTR1A
SCHEMBL31268960 0.90 LTB4R (0.34) CNR1PIK3CDPTGDR2HTR6HTR1A
SCHEMBL31269020 0.88 FFAR4 (0.38) CNR1PDE10APIK3CDPTGDR2HTR6
SCHEMBL31269133 0.86 PLA2G2A (0.38) CNR1PDE10APIK3CDPDE1BPTGDR2
SCHEMBL31268855 0.86 CNR1 (0.38) CNR1PIK3CDPDE1BPTGDR2HTR6
SCHEMBL31268850 0.85 FABP3 (0.36) CNR1PIK3CDPDE1BPTGDR2HTR6
SCHEMBL30983850 0.84 CNR1 (0.40) CNR1PDE10APIK3CDPDE1BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback